Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-06-01
DOI
10.3389/fonc.2021.645008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019
- (2020) Selma Ugurel et al. EUROPEAN JOURNAL OF CANCER
- BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma
- (2020) Bożena Cybulska-Stopa et al. MELANOMA RESEARCH
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- Constitutive Expression of NRAS with Q61R Driver Mutation Activates Processes of Epithelial–Mesenchymal Transition and Leads to Substantial Transcriptome Change of Nthy-ori 3–1 Thyroid Epithelial Cells
- (2019) D. E. Demin et al. BIOCHEMISTRY-MOSCOW
- Many ways to resistance: How melanoma cells evade targeted therapies
- (2019) Ines Kozar et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
- (2019) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma.
- (2019) Gabriella Liszkay et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
- (2019) Teofila Seremet et al. Journal of Translational Medicine
- Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
- (2019) Alessandro Rossi et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma
- (2019) Michele Guida et al. Cancers
- Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy
- (2018) Verena Haselmann et al. CLINICAL CHEMISTRY
- BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
- (2018) Jaquelyn N. Sanchez et al. DRUGS
- Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]
- (2018) Sara Valpione et al. EUROPEAN JOURNAL OF CANCER
- Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies
- (2018) Azad Saei et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy
- (2018) Teofila Seremet et al. MELANOMA RESEARCH
- Management of Metastatic Melanoma in 2018
- (2018) Howard L. Kaufman et al. JAMA Oncology
- Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.
- (2018) Brigitte Dreno et al. JOURNAL OF CLINICAL ONCOLOGY
- The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study
- (2018) Julia K. Tietze et al. Oncotarget
- 1244OKEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma
- (2018) P A Ascierto et al. ANNALS OF ONCOLOGY
- Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
- (2017) Michael A Davies et al. LANCET ONCOLOGY
- Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF V600 -mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial
- (2017) Max Schreuer et al. LANCET ONCOLOGY
- Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state
- (2017) Mohammad Fallahi‐Sichani et al. Molecular Systems Biology
- BRAF inhibitors: resistance and the promise of combination treatments for melanoma
- (2017) Merope Griffin et al. Oncotarget
- Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM).
- (2017) K. B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
- (2016) Matteo S Carlino et al. BRITISH JOURNAL OF CANCER
- Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy
- (2016) Michael P. Smith et al. CANCER CELL
- Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
- (2016) Max Schreuer et al. Journal of Translational Medicine
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
- (2016) Georgina V Long et al. LANCET ONCOLOGY
- Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
- (2016) Zachary A. Cooper et al. OncoImmunology
- Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells
- (2016) Yasmine Touil et al. Scientific Reports
- Treatment of NRAS-Mutant Melanoma
- (2015) Douglas B. Johnson et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Complete remission of metastatic melanoma upon BRAF inhibitor treatment – what happens after discontinuation?
- (2015) Henrike Tolk et al. MELANOMA RESEARCH
- Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR
- (2015) Miguel Vizoso et al. NATURE MEDICINE
- BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
- (2015) Francesco Spagnolo et al. OncoTargets and Therapy
- Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
- (2015) Francesco Spagnolo et al. Oncotarget
- The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition
- (2014) Matthew M. K. Chan et al. CANCER
- Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
- (2014) K. Kemper et al. CANCER RESEARCH
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- Finding the Right Balance of BRAF Inhibition in Melanoma
- (2014) M. A. Davies Cancer Discovery
- BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma
- (2014) S. M. Steinberg et al. Cancer Immunology Research
- Patterns of response and progression in patients withBRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib
- (2013) Mary W. F . Azer et al. CANCER
- The treatment of melanoma brain metastases before the advent of targeted therapies
- (2013) Stefania Vecchio et al. MELANOMA RESEARCH
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- BRAF inhibitor activity in V600R metastatic melanoma
- (2012) Oliver Klein et al. EUROPEAN JOURNAL OF CANCER
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Cycling toward Elimination of Leukemic Stem Cells
- (2010) Daniel Goff et al. Cell Stem Cell
- How melanomas bypass new therapy
- (2010) David Solit et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now